Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, Garrett G, Peel M, Outcalt R, Powell K, Trucksis M, Angulo D, Borroto-Esoda K.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02068-16. doi: 10.1128/AAC.02068-16. Print 2017 Apr.

2.

Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Lepak AJ, Marchillo K, Andes DR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. doi: 10.1128/AAC.04445-14. Epub 2014 Dec 15.

3.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8. doi: 10.1128/AAC.01354-13. Epub 2013 Sep 3.

4.

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.

Scorneaux B, Angulo D, Borroto-Esoda K, Ghannoum M, Peel M, Wring S.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01961-16. doi: 10.1128/AAC.01961-16. Print 2017 Mar.

5.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

6.

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.

Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N, Kovanda L, Borroto-Esoda K, Wring S, Angulo D, Ghannoum M.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02396-16. doi: 10.1128/AAC.02396-16. Print 2017 May.

7.

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Andes D, Marchillo K, Stamstad T, Conklin R.

Antimicrob Agents Chemother. 2003 Oct;47(10):3165-9.

8.

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ.

Antimicrob Agents Chemother. 2001 Oct;45(10):2845-55.

9.

Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Br├╝ggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01398-17. doi: 10.1128/AAC.01398-17. Print 2017 Dec.

10.

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jan;48(1):137-42.

11.

Pharmacokinetic/pharmacodynamic profile of posaconazole.

Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H.

Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000. Review.

PMID:
20481649
12.

Novel orally active inhibitors of ╬▓-1,3-glucan synthesis derived from enfumafungin.

Apgar JM, Wilkening RR, Greenlee ML, Balkovec JM, Flattery AM, Abruzzo GK, Galgoci AM, Giacobbe RA, Gill CJ, Hsu MJ, Liberator P, Misura AS, Motyl M, Nielsen Kahn J, Powles M, Racine F, Dragovic J, Habulihaz B, Fan W, Kirwan R, Lee S, Liu H, Mamai A, Nelson K, Peel M.

Bioorg Med Chem Lett. 2015 Dec 15;25(24):5813-8. doi: 10.1016/j.bmcl.2015.10.011. Epub 2015 Oct 9.

PMID:
26542966
13.
14.

Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.

Aviles P, Falcoz C, San Roman R, Gargallo-Viola D.

Antimicrob Agents Chemother. 2000 Sep;44(9):2333-40.

15.

Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn PA, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.

16.

Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.

Petraitiene R, Petraitis V, Hope WW, Walsh TJ.

Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S643-51. doi: 10.1093/cid/civ817.

17.

In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J.

Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503. doi: 10.1128/AAC.00478-08. Epub 2008 Jul 14.

18.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
19.

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J.

Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. Epub 2007 Dec 10.

20.

Supplemental Content

Support Center